Expand HCM Menu
HCM MENU

HCM Latest Press Releases

-- January 13, 2026 --

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet Globe Newswire 11:00 PM

-- January 6, 2026 --

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Globe Newswire 7:00 PM

-- January 4, 2026 --

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Nave Pancreatic Ductal Adenocarcinoma Globe Newswire 7:00 PM

-- December 30, 2025 --

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification Globe Newswire 5:00 AM

-- December 29, 2025 --

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma Globe Newswire 3:35 AM

-- December 16, 2025 --

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors Globe Newswire 7:00 PM

-- December 7, 2025 --

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China Globe Newswire 7:00 PM

-- November 26, 2025 --

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting Globe Newswire 7:00 PM

-- November 5, 2025 --

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing Globe Newswire 8:35 AM

-- November 4, 2025 --

HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS and TAGRISSO Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO Globe Newswire 7:00 PM
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS and TAGRISSO Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO Globe Newswire 7:00 PM

-- November 2, 2025 --

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event Globe Newswire 7:00 PM

-- October 31, 2025 --

CORRECTION -- International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025 Globe Newswire 8:35 AM

-- October 30, 2025 --

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 04, 2025 Globe Newswire 8:56 AM

-- October 22, 2025 --

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Globe Newswire 8:00 PM

-- October 14, 2025 --

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Globe Newswire 4:30 AM

-- October 13, 2025 --

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress Globe Newswire 12:00 AM

-- October 1, 2025 --

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 Globe Newswire 8:00 PM

-- September 11, 2025 --

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 Globe Newswire 8:00 PM

-- September 4, 2025 --

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 Globe Newswire 8:00 PM

-- August 24, 2025 --

HUTCHMED Announces Appointment of Acting Chief Executive Officer Globe Newswire 8:20 PM

-- August 19, 2025 --

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS and TAGRISSO Combination as a First-Line Therapy for Certain Lung Cancer Patients in China Globe Newswire 8:00 PM
Market Data Delayed 15 Minutes